Form 6-K Sanofi For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Oil rally pressures S&P, Nasdaq; Microsoft, Salesforce buoy Dow
- Oil prices rise 2% as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Lumentum shares fall after hitting 52-week high
Sanofi-Aventis (SNY) PT Raised to $60 at Argus
July 26, 2024 7:33 AM EDTArgus analyst Jasper Hellweg raised the price target on Sanofi-Aventis (NASDAQ: SNY) to $60.00 (from $55.00) while maintaining a Buy rating.
The analyst comments "Our rating on Sanofi SA (NGS: SNY), a leading global pharmaceutical company, is BUY. We like Sanofis diverse range of businesses, which include branded pharmaceuticals, generics, vaccines, and consumer healthcare products. The... More



